Re-Analysis of Three Network Meta-Analyses of Fluoxetine for Depression in Children and Adolescents: Clarifying Efficacy and Finding a Zombie

Add to your list(s) Download to your calendar using vCal

• Dr Martin Plöderl, Dr Florian Naudet, and Dr Richard Lyus
• Thursday 26 February 2026, 12:30-13:30
• Online via zoom.

If you have a question about this talk, please contact Oliver Knight.

Fluoxetine is recommended as the first-line medication for the treatment of depression in children and young people, typically based on the results of three network meta-analyses (NMAs) published in the last decade. However, two of these NMAs, published in Lancet journals, reported a moderate effect (SMD 0.5) with very low certainty; while the third, published by Cochrane, reported a small effect (SMD 0.2) with moderate certainty, which fell within the authors’ predetermined range of equivalence with placebo. The findings of the Lancet NMA might support the cautious use of fluoxetine, but the findings of the Cochrane NMA do not. We sought to explain this discrepancy.

This talk is part of the Department of Psychiatry & CPFT Thursday Lunchtime Seminar Series series.

This talk is included in these lists:

• Cardiovascular Epidemiology Unit Special Seminars
• Department of Psychiatry & CPFT Thursday Lunchtime Seminar
• Department of Psychiatry & CPFT Thursday Lunchtime Seminar Series
• Department of Psychiatry talks stream
• Department of Public Health and Primary Care
• Online via zoom
• PhD related
• Psychology talks and events
• PublicHealth@Cambridge
• Yishu's list
• my List

Note that ex-directory lists are not shown.